Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration

NCT03362190 is registered in ClinicalTrials.gov with Ophthotech Corporation as lead sponsor.

NCT NCT03362190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03362190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration
Lead sponsor
Ophthotech Corporation
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2017
Completion date
October 18, 2018
Enrollment
64 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration